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Abstract Negative psychological and physical effects of
prostate cancer and its medical treatment may persist
many years after diagnosis. The influence of a long
cycling tour on rehabilitative or health-related effects
with prostate cancer patients has not yet been studied.
In practice, physicians and therapists rarely recommend
cycling to prostate cancer. In May 2010, eight prostate
cancer patients rode their bikes for over 1,408 km from
Cologne to Marseille within 5 weeks. Endurance test,
blood examinations (prostate-specific antigen (PSA), to-
tal testosterone, interleukin-6, oxidative stress, and anti-
oxidant capacity) and quality of life questionnaires were
completed before and after the tour. All eight subjects
reached Marseille. Significant improvements could be
observed in physical performance and certain quality
of life scores (p=0.008), as well as a reduction of total
testosterone (p=0.19). PSA levels did not change. This
pilot study suggests that long bicycle tours with prostate
cancer patients are feasible. Due to the missing control
group and the small sample size, the results of this pilot study
are limited.
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Introduction
Every year, 60,120 men are diagnosed with prostate can-
cer, making it the most common malignant neoplasia in
men in Germany [25]. Prostate cancer and its medical
treatment cause a number of adverse effects on physical,
psychological, and social level. Eighteen months after
radical prostatectomy, 17–34 % of the men suffer from
urinary incontinence and up to 60 % experience erectile
dysfunction [33]. Hormone treatment can cause depressive
moods, hot flushes, impotence, blood loss, diarrhea, and
an increased body fat percentage [11, 13, 34, 36]. Addi-
tionally, muscular strength and bone density are reduced
during and after androgen-deprivation therapy [32]. Investi-
gations have shown that the risk of developing a metabolic
syndrome, diabetes mellitus, or cardiovascular disease
increases during a long-term hormone treatment [27, 34]. Also
psychological impacts, anxiety, sadness, and depressive syn-
dromes are often observed during medical treatment [8, 17].
Incontinence and impotence make patients feel uncomfortable
and ashamed and their self-esteem may be weakened [8, 17].
Psychological stress frequently causes sleep disturbances, fa-
tigue, nausea, and pain and negatively influences social skills
[19] and quality of life [17, 19, 37]. The resulting risk is that
patients underestimate their own performance due to insecu-
rity and therefore become physically inactive. This may then
lead to inactivity-induced health problems or even diseases
(Fig. 1).
In the last few years, several studies have shown that
physical activities are feasible and effective for prostate
cancer patients; not only during rehabilitation and in the
aftercare but also during the medical treatment [4]. Resis-
tance and aerobic exercise reduce fatigue and improve qual-
ity of life, muscular strength, and cardiovascular fitness
during irradiation [18, 31, 36, 39]. Positive influences on
muscular fitness, physical performance, fatigue, and quality
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of life have also been observed in patients undergoing
hormone treatment [5, 30]. Particularly, pelvic floor exer-
cises improve incontinence in affected men [15, 20]. Finally,
latest research suggests that the mortality risk is reduced in
physically active prostate cancer survivors [9]. Even though
the underlying effects are still unclear, an increased
interleukin-6 (IL-6) release [21] as well as a decreased
oxidative stress level is discussed [3]. The relevancy of the
sexual hormone testosterone is mostly unknown [26]. How-
ever, there are references that physical activity may influ-
ence total testosterone [14] as well as oxidative stress levels
[12] and interleukin-6 [21].
Even though cycling is a very popular sport in our soci-
ety, no studies could be found that examine the feasibility of
a bicycle tour which lasts for several weeks and involves
prostate cancer patients. This may be the reason why cycling
can hardly be found in physical exercise guidelines for
prostate cancer patients [28]. In practice, physicians and
therapists rarely recommend cycling to prostate cancer
patients due to insecurity, fear, and/or ignorance. Within this
pilot project, we evaluated the feasibility of a bicycle tour
with prostate cancer patients which lasted several weeks and
comprised 1,408 km.
Methods
Patient recruitment was conducted by a Federal Association
for Prostate Cancer Support (Bundesverband Prostatakrebs
Selbsthilfe). Inclusion criteria comprised diagnosed prostate
cancer, good German language skills, and a written consent
regarding participation in the study. Exclusion criteria were
serious cardiac disease (New York Heart Association Class
III–IV), severe orthopedic or internal disease that does not
allow a bicycle tour, pronounced oncological progress with-
in the last 12 months, brain and/or bone metastases, immu-
nosuppression, and/or acute health, and somatic restrictions
(e.g., infection, fever). A sports medical examination (e.g.,
anamnesis, electrocardiogram, etc.), which was conducted
3 months prior to the tour was meant to confirm safety.
The protocol was approved by the ethics committee of
the German Sport University Cologne and all procedures
are in accordance with the Helsinki Declaration of 1975.
All patients provided written informed consent prior to
participation.
Subjects
A total of 10 subjects were recruited. Two subjects had to be
excluded prior to the start of the tour due to orthopedic
complaints and an acute sport injury. Therefore, eight pros-
tate cancer patients participated in the bicycle tour. The
mean age of the patients was 66.87 years, the mean body
size was 180.37 cm, and the mean body weight was 88.0 kg
(Table 1). One participant dropped out during the follow-up
period (t4) without giving a reason.
Assessments
Assessments were conducted 3 months before (t1),
1 week before (t2), 1 week after (t3), and 6 months
after (t4) the bicycle tour. In order to assess aerobic
endurance, a spirometry on a cycle ergometer was con-
ducted (VO2max, lactate, and respiratory quotient). The
initial watt load of 60 W was increased every 5 min by
30 W with a 1-min break between each level. Spiroerg-
ometry is considered as the assessment method with the
highest validity [7].
Patients completed two quality of life questionnaires
(EORTC QLQ-C30 and PR25, version 3), which were
developed by “the European Organization for Research
and Treatment of Cancer ”(EORTC). The general ques-
tionnaire consists of 30 items, which result in five func-
tional scales (physical, cognitive, role, social, and emotional
functioning), three symptom scales (fatigue, nausea/vomiting,
and pain), a global scale concerning health-related qual-
ity of life, and six single items (dyspnoe, insomnia,
appetite loss, constipation, diarrhea, and financial dif-
ficulties). The prostate cancer-specific module EORTC
QLQ-PR25 contains 25 items. Its subscales include
three symptom scales (urinary, bowel, and treatment-
related symptoms), as well as a sexual function scale
[1]. Furthermore, the following blood parameters were
analyzed in a central laboratory: prostate-specific antigen
(PSA), total testosterone, and interleukin-6. For organizational
reasons, blood samples were only taken at t2, t3, and t4.
Oxidative stress levels and antioxidant capacities were exam-
ined by measuring the concentration of free oxygen radicals
(reactive oxygen species) and the antioxidant capacity
(antioxidants, antioxidant capacity) in patients’ capillary
blood (Fort and Ford Test, Company Incomat, Glashütten,
Germany) [12].
Loss of confidence in the own body
Lack of confidence in great physical efforts
Inactivity and social isolation
Inability to assess the own actual performance capacity
Model describing the influence of cancer diagnosis 
on self-confidence and physical activity level
Fig. 1 Model describing the influence of cancer diagnosis on self-
confidence and physical activity level
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The intervention
Eight prostate cancer patients took part in a 1,408 km
bicycles tour from the west of Germany to the south of
France. The tour started in May 2010 in Cologne and
went through Germany, Luxembourg, and France, all the
way to Marseille. The patients were accompanied by three
students. Two joined the patients on their bicycles, while
one drove the support car carrying luggage, food, and
service materials. The distances covered within the 21
daily stages ranged between 34 and 120 km per day (Ø
67 km). On average, participants rode their bikes for
4.35 h per day. In order to assess energy expenditure
and physical activity levels, four patients wore a Sense
Wear armband (SMT medical GmbH&Co Würzburg,
Germany) during the entire bicycle tour. Sense Wear is
a metabolic activity and lifestyle monitor, which determines
caloric expenditure [10]. The total time of travel added up to
approximately 91.50 h and a mean total energy expenditure of
95,974 kcal per person was reached. The group took three rest
days during their tour.
Statistics
Statistical analyses were performed using SPSS German
version 20.0 (IBM). In order to analyze the study data, the
median, standard deviation, and an analysis of variance was
applied. A one-factorial analysis of variance for repeated
measurements, including the Bonferroni post hoc test, was
employed. For graphical processing and representation of
the study data, the spreadsheet program Microsoft Office
Excel 2007 was used.
Results
All eight subjects reached Marseille within 5 weeks.
Patients were able to improve all aerobic endurance param-
eters throughout the tour. Lactate concentrations even
showed a (highly) significant development in the prepara-
tion phase from t1 to t2 measurement (Fig. 2). There was no
change from t2 to t3 but a slight decrease of lactate concen-
tration to t4.
Overall, the subjective parameters of quality of life showed
positive changes within this pilot study, even though these
rarely reached statistical significance. More noticeable,
changes were achieved in the prostate cancer-specific module
PR25. Clear improvements could be observed, including a
highly significant (p=0.008) effect on treatment-related qual-
ity of life (Table 2).
Regarding blood examinations, PSA concentrations did
not change in any subject throughout the bicycle tour and
therefore maintained stable. Interleukin-6 concentrations
remained constant from the first to the second measurement;
however, it increased 6 months after the intervention. Total
testosterone concentrations decreased clearly yet not signif-
icantly (p=0.19). Values remained in the normal range
(Table 3).
In terms of free radical determination, oxidative stress
levels remained nearly constant throughout the intervention.
Half a year after the bicycle tour, a nonsignificant decrease
Table 1 Subjects and anthropometric data
Subject Age Weight (kg) Height (cm) BMI (kg/m2) Diagnosis
1 67 86 182 25.96 Prostate cancer; p T2c; G2; Gleasen score, 3+3=6
2 67 95 185 27.76 Adenocarcinoma of the prostate pT3b; pN0 (0/23); cM0; G3; Gleason score, 4+4=8
3 69 93 173 31.07 Prostate cancer pT2c; pN0; pR1; G2; Gleason score, 3+3=6
4 66 80 185 23.37 Prostate cancer T2c; pN0; Gleason score, 3+4=7
5 66 82 176 26.47 Prostate cancer pT3b; pN0 (0/6); R0; G2b; Gleason score, 4+3=7
6 66 87 182 26.26 Adenocarcinoma of the prostate pT2b; pN0 (0/3); pMX; pL0; pV0; pR0;
Gleason score, 3+4=7
7 65 87 178 27.46 Prostate cancer T2c; N0; M0; G3; Gleason score, 5+5=10









Fig. 2 Changes in lactate concentrations from t1 (n=8, SA±0.84), t2
(n=8, SA±0.64), t3 (n=8, SA±0.47) and t4 (n=7, SA±0.79),
ANOVA, (standard deviation (SD), sample size (n), significance value
(p), significant (*), highly significant (**), not significant (n.s.) for all
p>0.05), t1, t2, t3, and t4
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could be observed (p=0.55). The antioxidant capacity in-
creased nearly significantly from t2 to t3 and then remained
stable in the follow-up period (p=0.063; Fig. 3).
Discussion
The results of this pilot study suggest that a long bicycle
tour with prostate cancer patients is feasible. With an appro-
priate preparation and medical investigation, it was possible
for each participant to accomplish the 1,408 km tour. Fur-
thermore, no problems appeared when realizing the project.
The findings show that above all, the aerobic endurance
performance of the prostate cancer patients improved
throughout and especially prior to the tour and in the follow
up. Therefore, the greatest effects were already achieved in
the preparation phase. Due to the fact that the patients began
the project with a good status of quality of life (corresponds
to mean value of the healthy population) [29, 36], signifi-
cant changes could barely be seen. Aside from the positive
psychosocial influence, PSA levels were not affected by the
bicycle tour. In literature, an increased PSA level is de-
scribed during or directly after a biking intervention. How-
ever, this observation is a short-term effect that is caused by
the mechanical stimulus during cycling [22]. In our results,
Table 2 Changes in quality of life from t1 (n=8) to t2 (n=8), t3 (n=8) and t4 (n=7), ANOVA (standard deviation (±SD), sample size (n),
significance value (p), significant (*), highly significant (**), not significant (n.s.) for all p>0.05) t1, t2, t3, and t4
T1 T2 T3 T4 p
EORTC QLQC-30
Quality of life 73.81±8.91 73.81±10.12 82.14±19.50 73.81±13.11 0.447
Physical functioning 98.09±3.25 93.33±5.44 98.10±5.04 95.24±9.97 0.139
Role functioning 95.24±12.60 95.24±12.60 95.24±12.60 88.10±15.85 0.415
Cognitive functioning 80.95±24.40 76.19±28.64 80.95±17.82 90.48±18.90 0.98
Social functioning 85.71±17.82 88.10±15.85 92.86±13.11 83.33±16.67 0.321
Emotional functioning 84.52±18.28 75.00±25.00 90.48±13.11 79.76±24.93 0.097
Fatigue 15.87±24.73 17.46±23.00 9.52±13.50 9.52±13.50 0.246
Nausea/vomiting 0±0 0±0 0±0 0±0 k.A.
Pain 14.29±20.25 4.76±8.13 11.90±20.89 19.05±26.23 0.488
Dyspnea 9.52±25.20 14.29±37.80 0±0 9.52±25.20 0.721
Insomnia 23.81±31.71 33.33±27.22 23.81±25.20 23.81±31.71 0.825
Appetite loss 0±0 0±0 4.76±12.60 0±0 0.415
Constipation 4.76±12.60 4.76±12.60 4.76±12.60 0±0 0.415
Diarrhea 4.76±12.60 4.76±12.60 4.76±12.60 0±0 0.761
Financial difficulties 0±0 0±0 0±0 4.76±12.60 0.415
EORTC PR 25
Sexual functioning 59.52±15.95 61.90±22.55 54.76±22.78 61.90±32.62 0.73
Urinary symptoms 22.88±25.32 25.33±25.95 22.29±23.29 27.38±25.06 0.07
Bowel symptoms 3.57±4.45 2.38±4.06 2.38±4.06 4.76±6.56 0.66
Treatment-related symptoms 19.84±13.90 11.91±16.17 8.41±12.03 13.33±14.55 0.008** (t1–t3: 0.006**)
Table 3 Changes in PSA, total testosterone, and interleukin-6 from t2
(n=8) to t3 (n=8) and t4 (n=7), ANOVA, (standard deviation (±SD),
sample size (n), significance value (p), for all p>0.05), t2, t3, and t4
Parameter t2 t3 t4 p value
Total testosterone 4.32±2.29 3.96±2.2 3.51±1.73 0.19
PSA 0.11±0.13 0.11±0.13 0.15±0.25 0.48
Interleukin-6 2.2±0.46 2.225±0.6 2.8±1.44 0.11






































Fig. 3 Changes in oxidative stress and antioxidant capacity from
1 week before (n=8; reactive oxygen species (ROS), SD ±97.16;
antioxidant capacity (AoC), SD ±0.64) to 1 week after (n=8; ROS,
SD ±48.4; AoC, SD ±0.69) and 6 months after the bicycle tour (n=7;
ROS, SD ±83.35; AoC, SD ±0.28), ANOVA (standard deviation (SD),
sample size (n), significance value (p) for all p>0.05)
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we observed a long-term effect. Total testosterone levels did
not change throughout the 5-week tour but then decreased in
the follow-up period. These findings correspond with recent
data. However, since two patients received an androgen dep-
rivation therapy, the interpretation of the results is limited. It is
scientifically well proven that long-term physical exercise can
decrease total testosterone levels in healthy athletes. Acute
impacts on the other hand can increase total testosterone [6,
16, 24]. These issues are mostly unexplored in cancer patients
[31]. Changes in IL-6 serum levels could not be detected.
Physical activity has a strong immediate effect on the IL-6
concentration which is associated with a long-term change
towards an anti-inflammatory environment in the organism.
Yet the scientific data is inconsistent [35, 38]. In the future,
studies with long follow-up periods should be considered.
When regarding the oxidative parameters, it is remarkable
that both oxidative stress and antioxidant capacity values
improve. It is well proven that high physical impacts increase
oxidative stress levels but long-term exercise interventions
decrease them, as could be shown in this pilot study [2, 12,
23]. Antioxidant capacity levels meet the standard range at all
assessment time points and even increased towards an upper
standard range after the tour.
The limitations of this pilot study are the small, heterogenic
sample size and the missing control group. In order to gain
further information on the impact of such a physical exercise
program on biological markers in prostate cancer patients, more
detailed research is necessary. We involved subjects which
already had a good quality of life and physical performance
at baseline. Therefore, greater effects could hardly be expected.
Yet, in summary, our results show that long cycling tours with
prostate cancer patients are feasible and could bring about long-
lasting positive effects. This most likely will increase physical
activity levels in prostate cancer patients and may therefore
counteract inactivity-induced health problems or diseases. Fi-
nally, this can also be of particular interest for the sport tourism
sector. Based on these findings, further studies must follow in
order to optimize therapeutic aspects of physical activities in
the rehabilitation and aftercare of a prostate cancer disease.
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